UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) June 23, 2020

 

LEXARIA BIOSCIENCE CORP.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-52138

 

20-2000871

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

100 – 740 McCurdy Road, Kelowna, BC Canada

 

V1X 2P7

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (250) 765-6424

 

N/A

(Former name or former address, if changed since last report.) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders

 

On June 23, 2020 at 1:00 p.m. (Pacific Time), Lexaria Bioscience Corp. (the “Company”) held its annual and special meeting of shareholders (the “Meeting”). There were 47,819,789 shares of the Company represented in person or by proxy at the meeting, constituting 53.38% of the Company’s issued share capital as at May 13, 2020, being the record date of the Meeting. The matters voted upon at the Meeting and the final voting results are set forth below:

 

Matter Being Voted On

For

Against

Abstain or

Withheld

Broker

Non-Vote

Percent

Approved By

To Elect Chris Bunka as a director

27,316,752

0

655,858

19,847,179

97.66%

To Elect John Docherty as a director

27,303,792

0

668,818

19,847,179

97.61%

To Elect Nicholas Baxter as a director

27,299,254

0

673,356

19,847,179

97.59%

To Elect Ted McKechnie as a director

27,238,991

0

733,619

19,847,179

97.38%

To Elect Brian Quigley as a director

27,338,170

0

634,440

19,847,179

97.73%

To Appoint Davidson & Company LLP as Auditors

47,364,520

0

455,269

0

99.05%

To Approve a Reverse Stock Split on a ratio of not less than 2 current shares for one reverse stock split share and not more than 30 current shares for one reverse stock split share

43,806,148

3,808,046

205,594

1

91.61%

To Approve an amendment to the Company’s Bylaws

26,579,677

1,094,414

298,519

19,847,179

95.02%

To ratify the lawful actions of the directors for the past year

27,089,295

497,896

385,419

19,847,179

96.84%

 

All of the proposals are described in detail in the Company’s proxy statement filed with the Securities Exchange Commission on May 25, 2020.

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

LEXARIA BIOSCIENCE CORP.

 

 

 

/s/ Chris Bunka

 

Chris Bunka

 

CEO, Principal Executive Officer

 

 

 

Date: June 24, 2020

 

 

 

 

3